Abstract
It appears that selective Cox-2 inhibitors do not affect the gastro duodenal mucosa whilst having antiinflammatory and analgesic efficacy similar to non-selective NSAIDs. Two broad categories of drugs are Cox-2 selective: coxibs and a number of pre-existing NSAIDs retrospectively found to have selectivity. Cox-2 inhibitors cause less dyspepsia than NSAIDs. They spare gastrointestinal mucosal generation of prostaglandins (PGs) and PGdependant bicarbonate secretion. Coxibs cause no acute mucosal injury in endoscopic studies and serendipitous Cox-2 inhibitors generally cause less acute injury than non -selective NSAIDs or placebo. Both celecoxib and rofecoxib have been associated with a substantial reduction in endoscopic ulcers compared to NSAID comparators. In the VIGOR study all upper GI events were reduced from 4.5 per 100 patient years to 2.1 per 100 patient years with supra-therapeutic doses of rofecoxib compared with naproxen. In the CLASS study, over a period of 3 days to 6 months, incidence of ulcer complications was 0.76% with celecoxib and 1.45% for ibuprofen or diclofenac. The less substantial reduction in events in the CLASS study compared with the VIGOR may be due, at least in part, to the fact that 21% of the patients were also on low dose aspirin. However it is premature to say that the benefit of Cox-2 inhibitors is lost in patients taking aspirin. There is continuing debate on the role of Cox-2 inhibitors in patients who have other risk factors for complicated ulcer disease e.g. patients who are elderly, on aspirin or corticosteroids, have a previous ulcer or have H. pylori infection.
Keywords: gastrointestinal safety, cox-2 inhibitor, rofecoxib, nsaid toxicity
Current Pharmaceutical Design
Title: Gastrointestinal Safety of Selective COX-2 Inhibitors
Volume: 8 Issue: 12
Author(s): C. J. Hawkey and M. M. Skelly
Affiliation:
Keywords: gastrointestinal safety, cox-2 inhibitor, rofecoxib, nsaid toxicity
Abstract: It appears that selective Cox-2 inhibitors do not affect the gastro duodenal mucosa whilst having antiinflammatory and analgesic efficacy similar to non-selective NSAIDs. Two broad categories of drugs are Cox-2 selective: coxibs and a number of pre-existing NSAIDs retrospectively found to have selectivity. Cox-2 inhibitors cause less dyspepsia than NSAIDs. They spare gastrointestinal mucosal generation of prostaglandins (PGs) and PGdependant bicarbonate secretion. Coxibs cause no acute mucosal injury in endoscopic studies and serendipitous Cox-2 inhibitors generally cause less acute injury than non -selective NSAIDs or placebo. Both celecoxib and rofecoxib have been associated with a substantial reduction in endoscopic ulcers compared to NSAID comparators. In the VIGOR study all upper GI events were reduced from 4.5 per 100 patient years to 2.1 per 100 patient years with supra-therapeutic doses of rofecoxib compared with naproxen. In the CLASS study, over a period of 3 days to 6 months, incidence of ulcer complications was 0.76% with celecoxib and 1.45% for ibuprofen or diclofenac. The less substantial reduction in events in the CLASS study compared with the VIGOR may be due, at least in part, to the fact that 21% of the patients were also on low dose aspirin. However it is premature to say that the benefit of Cox-2 inhibitors is lost in patients taking aspirin. There is continuing debate on the role of Cox-2 inhibitors in patients who have other risk factors for complicated ulcer disease e.g. patients who are elderly, on aspirin or corticosteroids, have a previous ulcer or have H. pylori infection.
Export Options
About this article
Cite this article as:
Hawkey J. C. and Skelly M. M., Gastrointestinal Safety of Selective COX-2 Inhibitors, Current Pharmaceutical Design 2002; 8 (12) . https://dx.doi.org/10.2174/1381612023394999
DOI https://dx.doi.org/10.2174/1381612023394999 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Homochiral Drugs: A Demanding Tendency of the Pharmaceutical Industry
Current Medicinal Chemistry Protein kinases and the Hypoxia-Inducible Factor-1, two switches in angiogenesis
Current Pharmaceutical Design Altered Expression of microRNAs in Serum Extracellular Vesicles in Rats with Severe Burns during Shock Stage
Current Molecular Medicine Crystallization and Preliminary X-Ray Analysis of the Splice Variant of Human Ankyrin Repeat and Suppressor of Cytokine Signaling Box Protein 9 (hASB9-2)
Protein & Peptide Letters Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications
Current Nutrition & Food Science Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Neuroproteomics: Are We Biased in Our Representation of Molecular Targets Associated with Specific Domains? Implications in Biomarker Discovery
Current Proteomics Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Current Cancer Drug Targets Trends in Malignant Glioma Monoclonal Antibody Therapy
Current Cancer Therapy Reviews Expression and Significance of Th17 Cells and Related Factors in Patients with Autoimmune Hepatitis
Combinatorial Chemistry & High Throughput Screening Gastrointestinal Effects of Selective and Non-Selective Non-Steroidal Anti- Inflammatory Drugs
Current Pharmaceutical Design Recent Advances in Antiviral Agents: Established and Innovative Therapies for Viral Hepatitis
Mini-Reviews in Medicinal Chemistry Successful Screening of Large Encoded Combinatorial Libraries Leading to the Discovery of Novel p38 MAP Kinase Inhibitors
Combinatorial Chemistry & High Throughput Screening COVID-19 Pandemic: Current Scenario, Challenges and Future Perspectives
Coronaviruses Reactions, Anti-Alzheimer and Anti COX-2 Activities of 6-Pyridin-3-yl-1Hpyrazolo[ 3,4-b]pyridin-3-amines
Current Organic Chemistry Autism, Mitochondria and Polybrominated Diphenyl Ether Exposure
CNS & Neurological Disorders - Drug Targets The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Drug Targets in Infections with Other Emerging Viruses: Influenza Viruses, Metapneumovirus and Hantaviruses
Infectious Disorders - Drug Targets